- Compugen Ltd. (CGEN, Financial) to present AI/ML-driven research at major international scientific conferences.
- Research focuses on predicting immune evasion and immunotherapy resistance in TNBC subtypes.
- Presentations highlight Compugen's expertise in computational cancer biology.
Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company, will present its AI/ML-driven predictive computational research at two significant scientific conferences in 2025. The first presentation is scheduled for the Annual Congress of the European Association for Cancer Research in Lisbon, Portugal, from June 16-19. This session will focus on predicting immune evasion and immunotherapy resistance mechanisms associated with distinct Triple Negative Breast Cancer (TNBC) subtypes. The presentation, delivered by Amir Toporik, will be marked by poster number EACR25-3113 on June 18, 2025.
The second presentation will take place at the International Society for Computational Biology conference in Liverpool, UK, from July 20-24. This session will address the computational prediction of TNBC tumor subtypes using integrative single cell atlas analysis. The research underscores Compugen's capability in utilizing computational methods to decode complex cancer biology. The poster, presented by Dr. Itamar Borukhov, will be available under poster number 947.
Compugen, recognized for its computational discovery platform UnigenTM, continues to advance its therapeutic pipeline, which includes early-stage immuno-oncology programs. The presentation materials and posters will be accessible in the publications section of Compugen's website following the conferences.
